Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameDIMETHYL SULFOXIDE
Labeler / manufacturerRenova Pharmaceuticals LLC
RouteINTRAVESICAL
Drug classDrug class not supplied in source label
Product NDC84897-052
Label effective date2026-07-20
Official product label reference
Dimethyl Sulfoxide — Renova Pharmaceuticals LLC
This page contains 14 source sections for DIMETHYL SULFOXIDE, intravesical route. Label set 8f699de6-9d09-48da-9d95-4001d7008587, version 1.
Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.
Uses described in the label
INDICATIONS AND USAGE Dimethyl sulfoxide is indicated for the symptomatic relief of patients with interstitial cystitis. Dimethyl sulfoxide has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.
Dosage and administration — label text
DOSAGE AND ADMINISTRATION Instillation of 50 mL of dimethyl sulfoxide directly into the bladder may be accomplished by catheter or asepto syringe and allow to remain for 15 minutes. Application of an analgesic lubricant gel such as lidocaine jelly to the urethra is suggested prior to insertion of the catheter to avoid spasm. The medication is expelled by spontaneous voiding. It is recommended that the treatment be repeated every two weeks until maximum symptomatic relief is obtained. Thereafter, time intervals between therapy may be increased appropriately. Administration of oral analgesic medication or suppositories containing belladonna and opium prior to the instillation of dimethyl sulfoxide can reduce bladder spasm. In patients with severe interstitial cystitis with very sensitive bladders, the initial treatment, and possibly the second and third (depending on patient response) should be done under anesthesia. (Saddle block has been suggested).
Contraindications
CONTRAINDICATIONS None known.
Warnings
WARNINGS Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide. This hypersensitivity has been reported in one patients receiving intravesical dimethyl sulfoxide. The physician should be cognizant of this possibility in prescribing dimethyl sulfoxide. If anaphylactoid symptoms develop, appropriate therapy should be instituted.
Adverse reactions
ADVERSE REACTIONS A garlic-like taste may be noted by the patient within a few minutes after instillation of dimethyl sulfoxide. This taste may last several hours and because of the presence of metabolites, an odor on the breath and skin may remain for 72 hours. Transient chemical cystitis has been noted following instillation of dimethyl sulfoxide. The patient may experience moderately severe discomfort on administration. Usually this becomes less prominent with repeated administration.
Unclassified section
PRESCRIBING INFORMATION Rx only
Product description
DESCRIPTION Dimethyl Sulfoxide (DMSO) Irrigation, USP 50% w/w Aqueous Solution for intravesical instillation. Each mL contains 0.54 gm dimethyl sulfoxide STERILE AND NON-PYROGENIC. Intravesical instillation for the treatment of interstitial cystitis. NOT FOR INTRAMUSCULAR OR INTRAVENOUS INJECTION. The active component of irrigation is dimethyl sulfoxide which has the empirical formula C 2 H 6 OS, and is structurally represented as: Dimethyl sulfoxide is a clear, colorless and essentially odorless liquid which is miscible with water and most organic solvents. Other physical characteristics include: molecular weight 78.13, melting point 18.3°C, and a specific gravity of 1.096. image description
Clinical pharmacology
CLINICAL PHARMACOLOGY Dimethyl sulfoxide is metabolised in man by oxidation to dimethyl sulfone or by reduction to dimethyl sulfide. Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces. Dimethyl sulfide is eliminated through the breath and skin and is responsible for the characteristics odor from patients on dimethyl sulfoxide medication. Dimethyl sulfone can persist in serum for longer than two weeks after a single intravesical instillation. No residual accumulation of dimethyl sulfoxide has occurred in man or lower animals who have received treatment for protracted periods of time. Following topical application, dimethyl sulfoxide is absorbed and generally distributed in the tissues and body fluids.
Precautions
PRECAUTIONS Changes in the refractive index and lens opacities have been seen in monkeys, dogs and rabbits given high doses of dimethyl sulfoxide chronically. Since lens changes were noted in animals, full eye evaluations, including slit lamp examinations, are recommended prior to and periodically during treatment. Approximately every six months patients receiving dimethyl sulfoxide should have a biochemical screening, particularly liver and renal function tests, and complete blood count. Intravesical instillation of dimethyl sulfoxide may be harmful to patients with urinary tract malignancy because of dimethyl sulfoxide-induced vasodilation. Some data indicate that dimethyl sulfoxide potentiates other concomitantly administered medications. Dimethyl sulfoxide caused teratogenic responses in hamsters, rats and mice when administered intraperitoneally at high doses (2.5 to 12 gm/kg). Oral or topical doses of dimethyl sulfoxide did not cause problems of reproduction in rats, mice and hamsters. Topical doses (5 gm/kg first two days, then 2.5 gm/kg - last eight days) produced terata in rabbits, but in another study, topical doses of 1.1 gm/kg days 3 through 16 of gestation failed to produce any abnormalities. There are no adequate and well controlled studies in pregnant women. Dimethyl sulfoxide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dimethyl sulfoxide is administered to a nursing woman. Safety and effectiveness in children have not been established. Information available to be given to the patient is reprinted at the end of this text.
Drug abuse and dependence
DRUG ABUSE AND DEPENDENCE None known.
Overdose information
OVERDOSAGE The oral LD 50 of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of dimethyl sulfoxide in the patient. In case of accidental oral ingestion, specific measures should be taken to induce emesis. Additional measures which may be considered are gastric lavage, activated charcoal and force diuresis.
Supply and packaging
HOW SUPPLIED Vials contain 50 mL of sterile and non-pyrogenic dimethyl sulfoxide (50% w/w dimethyl sulfoxide aqueous solution). Dimethyl sulfoxide is clear and colorless. NDC 84897-052-01 carton containing a 50 mL vial Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from strong light. Distributed by: Renova Pharmaceuticals LLC 161 Dwight Place, Fairfield, NJ 07004 Rev. 06/2026
Storage and handling
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from strong light. Distributed by: Renova Pharmaceuticals LLC 161 Dwight Place, Fairfield, NJ 07004 Rev. 06/2026
Information for patients
INFORMATION FOR PATIENTS (Physician Copy) Dimethyl Sulfoxide is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis. Dimethyl Sulfoxide will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician. Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a Dimethyl Sulfoxide instillation. A garlic-like taste may be noted by the patient within a few minutes after instillation of Dimethyl Sulfoxide. This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours. Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration. If you are pregnant or nursing, ask your physician about the advisability of using Dimethyl Sulfoxide. Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment. Dimethyl Sulfoxide Irrigation, USP 50% w/w Distributed by: Renova Pharmaceuticals LLC 161 Dwight Place, Fairfield, NJ 07004 Rev. 06/2026 Code: PON/DRUGS/08 22 2288
INFORMATION FOR PATIENTS (Patient Copy) Dimethyl Sulfoxide is a sterile solution of 50% dimethyl sulfoxide (DMSO) and 50% water that has been approved by the U.S. Food and Drug Administration for use in the symptomatic relief of patients with interstitial cystitis. Dimethyl Sulfoxide will be instilled in the bladder on an inpatient or out-patient basis, which will be determined by your physician. Some data indicate that dimethyl sulfoxide could change the effectiveness of medication(s) that you may be presently receiving. Be sure to mention the name and dosage of all medicines you are taking to your physician before a Dimethyl Sulfoxide instillation. A garlic-like taste may be noted by the patient within a few minutes after instillation of Dimethyl Sulfoxide. This taste may last several hours. An odor on the breath and skin may be present and remain for up to 72 hours. Some patients may experience discomfort on administration of the drug. Usually this becomes less prominent with repeated administration. If you are pregnant or nursing, ask your physician about the advisability of using Dimethyl Sulfoxide. Some eye changes have been observed in animals treated with DMSO in large doses for prolonged periods. Therefore your doctor may want you to have eye evaluations, including slit lamp examinations prior to and periodically during treatment. Distributed by: Renova Pharmaceuticals LLC 161 Dwight Place, Fairfield, NJ 07004 Rev. 06/2026
The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.